XF-73 Phase 2b data to be presented at ECCMID

Friday July 9, 2021

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress

  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 9th July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of XF-73 nasal gel will be presented at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on Saturday, 10 July at 7:35 pm CET

Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study.

Presenting Author: Julie Mangino MD, FSHEA, FIDSA, Professor Emeritus, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University College of Medicine, US

Abstract #: 04905

Session: LB: Late breaking clinical trial data

Session code: S182

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit  https://www.destinypharma.com


ECCMID (https://www.eccmid.org/) is Europe’s premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise. The scientific programme is built by the ECCMID Programme Committee, and independent group of experts representing all disciplines related to clinical microbiology and infectious diseases.

About XF-73

XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.